AstraZeneca PLC (AZN)vsRigel Pharmaceuticals Inc (RIGL)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
RIGL
Rigel Pharmaceuticals Inc
$29.93
-1.06%
HEALTHCARE · Cap: $593.55M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20062% more annual revenue ($60.44B vs $299.77M). RIGL leads profitability with a 121.5% profit margin vs 17.2%. RIGL trades at a lower P/E of 1.7x. RIGL earns a higher WallStSmart Score of 65/100 (B-).
AZN
Buy64
out of 100
Grade: C+
RIGL
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+87.7%
Fair Value
$283.28
Current Price
$29.93
$253.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 91 in profit
Keeps 122 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Earnings declined 30.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 121.5% and operating margin at 20.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
RIGL carries more volatility with a beta of 1.18 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RIGL scores higher overall (65/100 vs 64/100), backed by strong 121.5% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?